A5034032647- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Preterm Birth and Chorioamnionitis
- Gastric Cancer Management and Outcomes
- CNS Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- T-cell and B-cell Immunology
- Reproductive System and Pregnancy
- Immunotherapy and Immune Responses
- Helicobacter pylori-related gastroenterology studies
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Cutaneous lymphoproliferative disorders research
- Neonatal Respiratory Health Research
- Long-Term Effects of COVID-19
- Head and Neck Cancer Studies
- Reproductive tract infections research
- Immune cells in cancer
Memorial Sloan Kettering Cancer Center
2015-2025
Kettering University
2020-2024
Cornell University
2003-2024
New York Hospital Queens
2024
Presbyterian Hospital
2024
NewYork–Presbyterian Hospital
2024
Weill Cornell Medicine
2024
Parker Institute for Cancer Immunotherapy
2020-2023
Lymphoma Research Foundation
2023
Leukemia and Lymphoma Society
2020-2022
The novel 2019 strain of coronavirus is a source profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has relatively high rate, the reasons for which are not entirely clear. Furthermore, treatment options currently limited. In this Perspective, we explore contributions innate adaptive immune systems to both control as well toxicity during infections offer suggestions understand therapeutically modulate anti-COVID immunity.
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients who were hospitalized for COVID-19, hematologic had higher relative to solid cancer. two additional cohorts, flow cytometric serologic analyses demonstrated without similar phenotype during acute whereas impairment B cells severe respiratory syndrome 2 (SARS-CoV-2)-specific antibody responses. Despite impaired...
We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550).Transplant eligible patients with rel/ref cHL following first-line were treated two to four cycles of (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 8), vinorelbine (20 (15 mg/m2, given on 21-day cycles. The...
We have investigated the function of endogenous galectin-3 in T cells. Galectin-3-deficient (gal3 −/− ) CD4 + cells secreted more IFN-γ and IL-4 than gal3 +/+ after T-cell receptor (TCR) engagement. Galectin-3 was recruited to cytoplasmic side immunological synapse (IS) activated In stimulated on supported lipid bilayers, primarily located at peripheral supramolecular activation cluster (pSMAC). Gal3 formed central SMAC bilayers less effectively adhered antigen-presenting firmly cells,...
BACKGROUND. Understanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study allogeneic (Allo) autologous (Auto) hematopoietic cell transplant CD19-directed chimeric antigen receptor T (CAR T) at Memorial Sloan Kettering Cancer Center, we aimed identify clinical variables associated severity assess lymphocyte populations.
Abstract Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and persistent and/or recurrent patients with hematologic malignancies, but the drivers of this population are unknown. We found that B-cell lymphomas were at particularly high risk for severe respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity. Further analysis these identified discrete factors initial severity compared chronicity. Active therapy diminished T-cell counts COVID-19–infected lymphoma....
Immune recovery post–cellular therapies is an important predictor of response to the anti–SARS-CoV-2 vaccine and can be used guide timing primary vaccination, as well booster vaccine, after therapy.
The interaction between a T cell and an antigen-presenting (APC) can trigger signaling response that leads to activation. Prior studies have shown ligation of the receptor (TCR) triggers cascade proceeds through coalescence TCR various molecules (e.g., kinase Lck adaptor protein LAT [linker for activation]) into microdomains on plasma membrane. In this study, we investigated another ligand-receptor (CD58-CD2) facilities activation using model system consisting Jurkat cells interacting with...
Abstract Short-lived TCR microclusters and a longer-lived protein kinase Cθ-focusing central supramolecular activation cluster (cSMAC) have been defined in model immunological synapses (IS). In different systems, CD28-mediated costimulatory interactions detected microclusters, the cSMAC, or segregated from forming multiple distinct foci. The relationship between molecules physiological IS of T cell-dendritic cell (DC) is obscure. To study dynamic CD28-CD80 cell-DC during Ag-specific...